Enhancing and Evolving INFRAFRONTIER Disease Modelling Capacity to Enable Breakthrough Research

Información del proyecto

INFRAPLUS

Identificador del acuerdo de subvención: 101131669

DOI

10.3030/101131669

Fecha de la firma de la CE 20 Junio 2024

Fecha de inicio 1 Junio 2024

Fecha de finalización 31 Mayo 2027

Financiado con arreglo a

• Research infrastructures

Coste total

€ 4 999 863,75

Aportación de la UE

€ 3 999 891,00

Coordinado por

INFRAFRONTIER ERIC
Germany

Periodic Reporting for period 1 - INFRAPLUS (Enhancing and Evolving INFRAFRONTIER Disease Modelling Capacity to Enable Breakthrough Research)

Período documentado: 2024-06-01 hasta 2025-11-30

Resumen del contexto y de los objetivos generales del proyecto

INFRAPLUS aims at bringing INFRAFRONTIER resources and services even closer to human application by enhancing INFRAFRONTIER's capacity for human disease modelling and reacting to global biomedical challenges. This proposal focuses on 1) enhancing rodent models for human disease modelling to address complex biomedical investigations; 2) developing complementary in vitro disease models to provide validated alternatives to animal models; 3) providing an innovative portfolio of high-quality disease-oriented screening services with a defined business model specifically targeting preclinical research; and 4) strengthening data-centric activities like enrichment of genetic and phenotypic datasets from mouse models to make them compliant with FAIR (Findable, Accessible, Interoperable, Reusable) standards and translatable, and the provision of novel machine learning-based analytical services. A strong focus on reducing and refining animal research and reducing the environmental impact of INFRAFRONTIER activities is also included in the proposed activities.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

The Specific Objectives (SO), the corresponding activities and main achievements are listed below:

SO.1: Advancing INFRAFRONTIER's capacity for modelling human diseases (WP1-4).
Progress towards SO.1 in RP1: In WP1-4, the objective of advancing INFRAFRONTIER’s disease modelling capacity is being realised by assessing and cataloguing gene editing technologies (Task 1.1 and Task 1.2) providing access to pilot services via Open Calls (Task 1.3 Task 1.4 and Task 2.4) developing state-of-the-art in vitro models for service provision (Task 2.1 Task 2.2 and Task 2.3) compiling a disease-oriented screening portfolio (task 3.1) consolidation of SOPs for preclinical evaluation (Task 3.2) evaluating specialised preclinical platforms for service provision (Task 3.3) and developing Machine Learning (ML)-based data analysis tools for service provision (Task 4.3).

SO.2: Developing national node capacities and expertise for providing innovative in vivo, in vitro, preclinical and data analysis services. (WP5)
Progress towards SO.2 in RP1: To achieve this objective WP5 assessed the technical needs of the INFRAPLUS partners. The results of this survey are currently being utilised to match interested personnel with ongoing training courses offered by the project partners or to design novel training courses and webinars especially on in vitro technologies.

SO.3: Augmenting novel model systems and services with the requirements and demands of existing and novel user communities. (WP1-4, WP7)
Progress towards SO.3 in RP1: suggestions for improvement and refinement of the pilot services was collected from the userbase using a specialised survey. The information gathered will be used in creating a final service provision plan.

SO.4: Refining the INFRAFRONTIER service portfolio by focusing on reducing animal usage, refining new technologies, emphasising alternative cellular models, reducing environmental impact and optimisation of resources. (WP6)
Progress towards SO.4 in RP1: WP6 moved forward this objective by gathering information on animal welfare and 3R principle on all INFRAPLUS activities and initiating the process of creating environmental sustainability guidelines by complementing the needs of new animal facilities that are under construction. In addition, the Ethics Advisory Board were present at the INFRAFRONTIER Conference 2025 and attended the internal WP Leads Calls to discuss the ethical aspects of the project.

SO.5 Raising awareness of INFRAFRONTIER’s cutting-edge services for modelling human diseases (WP7)
Progress towards SO.5 in RP1: WP7 has pushed this continuous objective throughout RP1 via various means detailed in 1.2.7 below. A specific achievement has been the successful organisation of the ‘INFRAFRONTIER Conference 2025: Human Disease Modelling in Rare Diseases’.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

The following are the key results achieved in RP1:
R1. INFRAPLUS Pilot Services (WP1, WP2): The three pilot services will evolve INFRAFRONTIER’s disease modelling capacity and fill in access provision gaps in the biomedical community.
Impact: Increased long-term sustainability and enabling breakthrough research and innovation.

R6. Expanded model data curation capability (WP4): Ongoing implementation of in-depth data curation and annotation workflows for new disease models.
Impact: Enabling breakthrough research and innovation and reinforcing ERA's competitiveness.

R9. Training programmes (WP5): Trainings delivered based on the needs of the RI staff with the aim of increasing service provision capacity.
Impact: Reinforcing ERA's competitiveness and optimising the ERI landscape and lead to better structuring and strengthening of INFRAFRONTIER national nodes.